THE ANALYSIS OF CD44 ALTERNATIVE SPLICING PATTERN IN UROLOGIC CANCER

我们开发了CD44-Competitive-RT-PCR，这是一种高度敏感的方法，足以在更大的非肿瘤细胞群中检测过表达CD44R1的稀疏肿瘤细胞。该技术应用于50例尿液标本，以探讨肿瘤细胞的检测是否可用于临床诊断癌症。CD44R1对CD44R2转录物的相对表达可以通过CD44-Competitive-RT-PCR进行定量，以内源性CD44R2转录物作为内部标准竞争RNA。在30例未见瘤变的标本中，比值不超过1。另一方面，在剩余的20例尿路癌患者标本中，cd44竞争性rt - pcr检测正确识别了13例标本。该检测诊断癌症的敏感性和特异性分别为65%和100%。

We have developed CD44-Competitive-RT-PCR which is highly sensitive method enough to detect sparse tumor cells overexpressing CD44R1 among a much larger population of non-neoplastic cells. This technique was applied to 50 urine specimens to investigate whether the detection of tumor cells could be clinically useful in diagnosing cancer. The relative expression of CD44R1 to CD44R2 transcript can be quantified by CD44-Competitive-RT-PCR using endogenous CD44R2 transcript as the internal standard competitor RNA.In 30 specimens with no evidence of neoplasia, the ratio does not exceed 1. On the other hand, in the remaining 20 specimens from patients with urinary tract cancer, the CD44-competitive-RT-PCR assay correctly identified 13 specimens. The sensitivity and specificity of this assay for a diagnosis of cancer was 65% and 100%, respectively.